CNS Pharmaceuticals, Inc. (CNSP)
| Market Cap | 6.97M +50.5% |
| Revenue (ttm) | n/a |
| Net Income | -16.70M |
| EPS | -7.66 |
| Shares Out | 1.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,389 |
| Open | 4.600 |
| Previous Close | 4.510 |
| Day's Range | 4.350 - 5.190 |
| 52-Week Range | 1.900 - 10.540 |
| Beta | 1.02 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of g... [Read more]
Financial Performance
Financial StatementsNews
CNS Pharmaceuticals details business development strategy
CNS Pharmaceuticals (CNSP) participated in a Virtual Investor “What This Means” Segment in which Chief Business Officer Dylan Wenke provided an update on its business development strategy as part of…
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (N...
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipel...
CNS Pharmaceuticals Proxy statement: Proxy filing
CNS Pharmaceuticals filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
CNS Pharmaceuticals Proxy statement: Proxy filing
CNS Pharmaceuticals filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
CNS Pharmaceuticals Slides: Investor presentation
CNS Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
CNS Pharmaceuticals reports Q2 EPS (37c) vs. ($6.42) last year
“We are moving with speed and discipline to transform this company,” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals (CNSP). “In the second quarter, we significantly stre...
CNS Pharmaceuticals ‘actively evaluating’ business devlopment opportunities
The company said, “Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team’s multi-functional experien...
CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months
Cash and cash equivalents were approximately $20.0 million as of June 30, 2026, compared to $7.2 million as of December 31, 2025. The increase primarily reflects the Company’s previously announced…
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipe...
CNS Pharmaceuticals Quarterly report: Q2 2026
CNS Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
CNS Pharmaceuticals Earnings release: Q2 2026
CNS Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innov...
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipel...
CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders
16:57 EDT CNS Pharmaceuticals (CNSP) files to sell 9.79M shares of common stock for holders
CNS Pharmaceuticals Registration statement: Registration filing
CNS Pharmaceuticals filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year
“We believe CNS Pharmaceuticals (CNSP) has entered a transformational new phase defined by strategic clarity, financial strength and disciplined execution,” said Rami Levin, President and Chief Execut...
CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months
Cash and cash equivalents were $2,951,000 as of March 31, 2026. The cash balance on March 31, 2026 does not account for the gross proceeds from the $22.5 million private…
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with i...
CNS Pharmaceuticals Quarterly report: Q1 2026
CNS Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
CNS Pharmaceuticals Earnings release: Q1 2026
CNS Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
3 Penny Stocks to Watch Now, 5/5/26
CNS Pharmaceuticals ($CNSP), Elong Power Holding ($ELPW), and Skycorp Solar Group ($PN) are the three penny stocks to watch on May 5, according to TipRanks’ Penny Stock Screener tool. Penny…
Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?
CNS Pharmaceuticals stock underwent a massive rally alongside a $22.5 million private placement.
CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement
CNS Pharmaceuticals (CNSP) entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5M to the Company, before pla...
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to e...